Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 17 | 2026 | 358 | 6.720 |
Why?
|
| Thymus Gland | 8 | 2020 | 205 | 2.300 |
Why?
|
| Autoantigens | 7 | 2025 | 146 | 1.900 |
Why?
|
| Immune Tolerance | 8 | 2025 | 388 | 1.840 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2018 | 168 | 1.510 |
Why?
|
| Autoimmunity | 4 | 2025 | 195 | 1.460 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2026 | 454 | 1.130 |
Why?
|
| Prostate | 4 | 2016 | 434 | 1.090 |
Why?
|
| Cell Differentiation | 8 | 2026 | 1656 | 1.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2021 | 701 | 0.980 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 1846 | 0.900 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2023 | 507 | 0.880 |
Why?
|
| Clone Cells | 7 | 2023 | 223 | 0.790 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 223 | 0.720 |
Why?
|
| Antigen Presentation | 4 | 2020 | 234 | 0.710 |
Why?
|
| Neoplasms | 5 | 2018 | 3382 | 0.710 |
Why?
|
| Lymphocyte Activation | 7 | 2021 | 825 | 0.700 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2020 | 291 | 0.680 |
Why?
|
| Animals | 28 | 2026 | 29045 | 0.670 |
Why?
|
| Mice | 21 | 2025 | 12762 | 0.670 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2017 | 99 | 0.660 |
Why?
|
| Transcription Factors | 4 | 2016 | 1724 | 0.600 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 3628 | 0.600 |
Why?
|
| Lymphopoiesis | 1 | 2020 | 48 | 0.590 |
Why?
|
| Dendritic Cells | 3 | 2021 | 547 | 0.570 |
Why?
|
| T-Lymphocytes | 4 | 2015 | 1335 | 0.560 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 140 | 0.560 |
Why?
|
| Clonal Selection, Antigen-Mediated | 4 | 2020 | 8 | 0.540 |
Why?
|
| Forkhead Transcription Factors | 4 | 2025 | 185 | 0.510 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 366 | 0.500 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 2 | 2019 | 51 | 0.500 |
Why?
|
| Mice, Transgenic | 7 | 2025 | 1608 | 0.490 |
Why?
|
| Self Tolerance | 1 | 2016 | 26 | 0.470 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 1107 | 0.420 |
Why?
|
| Repressor Proteins | 2 | 2019 | 450 | 0.400 |
Why?
|
| Mice, Knockout | 6 | 2020 | 2217 | 0.330 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 336 | 0.310 |
Why?
|
| Peptides | 3 | 2021 | 671 | 0.290 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2021 | 174 | 0.280 |
Why?
|
| Male | 20 | 2025 | 47475 | 0.280 |
Why?
|
| Clonal Deletion | 2 | 2020 | 24 | 0.270 |
Why?
|
| Antigen-Presenting Cells | 3 | 2020 | 147 | 0.250 |
Why?
|
| Antigens | 2 | 2021 | 225 | 0.240 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 201 | 0.230 |
Why?
|
| Histones | 1 | 2008 | 365 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 1215 | 0.210 |
Why?
|
| Graft vs Host Disease | 2 | 2019 | 382 | 0.210 |
Why?
|
| Humans | 25 | 2026 | 98799 | 0.200 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 621 | 0.200 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 99 | 0.190 |
Why?
|
| Ligands | 3 | 2021 | 492 | 0.190 |
Why?
|
| Lymphocyte Depletion | 2 | 2021 | 103 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 583 | 0.190 |
Why?
|
| Cell Lineage | 2 | 2016 | 334 | 0.190 |
Why?
|
| Cell Line | 3 | 2021 | 2484 | 0.180 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2023 | 150 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 2 | 2017 | 453 | 0.180 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 15 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 51 | 0.170 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 18 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 78 | 0.170 |
Why?
|
| Carcinogens | 1 | 2021 | 102 | 0.170 |
Why?
|
| Insulin | 3 | 2017 | 1226 | 0.170 |
Why?
|
| Quinolones | 1 | 2021 | 59 | 0.170 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2011 | 0.170 |
Why?
|
| Feedback, Physiological | 1 | 2021 | 71 | 0.160 |
Why?
|
| Insecta | 1 | 2021 | 58 | 0.160 |
Why?
|
| Cell Movement | 2 | 2016 | 821 | 0.160 |
Why?
|
| Saliva | 1 | 2021 | 134 | 0.160 |
Why?
|
| CD8 Antigens | 2 | 2019 | 82 | 0.150 |
Why?
|
| Glucose Tolerance Test | 3 | 2017 | 239 | 0.150 |
Why?
|
| Tumor Escape | 2 | 2018 | 56 | 0.150 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 218 | 0.150 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2019 | 41 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2020 | 192 | 0.140 |
Why?
|
| Dietary Sucrose | 1 | 1998 | 14 | 0.140 |
Why?
|
| Homeostasis | 1 | 2021 | 474 | 0.140 |
Why?
|
| Energy Intake | 1 | 1998 | 100 | 0.140 |
Why?
|
| Female | 15 | 2025 | 51997 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 1998 | 173 | 0.130 |
Why?
|
| Arginine | 2 | 2017 | 144 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2018 | 65 | 0.130 |
Why?
|
| Tight Junctions | 1 | 2019 | 158 | 0.130 |
Why?
|
| Epitope Mapping | 1 | 2017 | 18 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2020 | 742 | 0.130 |
Why?
|
| Coronary Disease | 1 | 1998 | 227 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 57 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2016 | 43 | 0.120 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 8 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 563 | 0.120 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 20 | 0.120 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 42 | 0.120 |
Why?
|
| B7-1 Antigen | 1 | 2016 | 75 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2017 | 286 | 0.120 |
Why?
|
| Phenotype | 1 | 2023 | 2673 | 0.120 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Biomarkers | 2 | 2020 | 2026 | 0.110 |
Why?
|
| B7 Antigens | 1 | 2015 | 7 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1091 | 0.110 |
Why?
|
| Glucagon | 1 | 2014 | 114 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2015 | 355 | 0.100 |
Why?
|
| Major Histocompatibility Complex | 1 | 2014 | 89 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 846 | 0.100 |
Why?
|
| Research Design | 1 | 2017 | 652 | 0.100 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2013 | 48 | 0.100 |
Why?
|
| CD4 Antigens | 1 | 2013 | 81 | 0.090 |
Why?
|
| Kinetics | 4 | 2014 | 1478 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1786 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 298 | 0.090 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 91 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2013 | 187 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 979 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1293 | 0.090 |
Why?
|
| Haplotypes | 1 | 2013 | 657 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 356 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 1806 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 568 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 357 | 0.070 |
Why?
|
| Hybridomas | 1 | 2008 | 61 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2014 | 722 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2008 | 480 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2008 | 174 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 117 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2012 | 831 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 403 | 0.060 |
Why?
|
| Melanoma | 2 | 1999 | 523 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2014 | 915 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 2077 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 519 | 0.050 |
Why?
|
| HLA-A2 Antigen | 2 | 1999 | 32 | 0.050 |
Why?
|
| Middle Aged | 7 | 2021 | 29642 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 1999 | 161 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2021 | 32 | 0.040 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2001 | 9 | 0.040 |
Why?
|
| Membrane Microdomains | 1 | 2021 | 52 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2001 | 26 | 0.040 |
Why?
|
| Half-Life | 1 | 2001 | 90 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2021 | 86 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2002 | 176 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2021 | 246 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2002 | 250 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 162 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 301 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 289 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 336 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 327 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 889 | 0.040 |
Why?
|
| Integrin alpha Chains | 1 | 2019 | 21 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1999 | 43 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 1999 | 42 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 3058 | 0.040 |
Why?
|
| Diet Surveys | 1 | 1998 | 21 | 0.040 |
Why?
|
| Risk Factors | 3 | 2016 | 6295 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 221 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2002 | 923 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1999 | 205 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 322 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2017 | 40 | 0.030 |
Why?
|
| Adult | 6 | 2021 | 29698 | 0.030 |
Why?
|
| Linear Models | 1 | 1998 | 428 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 44 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 482 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 1396 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 1113 | 0.030 |
Why?
|
| Binding Sites | 1 | 1999 | 1162 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2581 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 3642 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 1007 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 828 | 0.030 |
Why?
|
| Obesity | 3 | 2014 | 1079 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1801 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 228 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 824 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2017 | 392 | 0.030 |
Why?
|
| Paresthesia | 1 | 2014 | 24 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 95 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1305 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 72 | 0.030 |
Why?
|
| C-Peptide | 1 | 2014 | 192 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 218 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 330 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 96 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 374 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2014 | 187 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 32 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 71 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 313 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 466 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 83 | 0.020 |
Why?
|
| Immunologic Surveillance | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 102 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 389 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 791 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 1029 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 869 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 2 | 1999 | 12 | 0.020 |
Why?
|
| MART-1 Antigen | 2 | 1999 | 21 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 999 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2076 | 0.020 |
Why?
|
| Mutation | 1 | 2001 | 4443 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 384 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1275 | 0.020 |
Why?
|
| Aged | 3 | 2014 | 21986 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2799 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 1999 | 446 | 0.020 |
Why?
|
| Adolescent | 2 | 1998 | 10168 | 0.010 |
Why?
|
| Neoplasm Proteins | 2 | 1999 | 553 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 2 | 1980 | 37 | 0.010 |
Why?
|
| Diabetes Mellitus | 2 | 2002 | 815 | 0.010 |
Why?
|
| Triglycerides | 2 | 1980 | 234 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 7598 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1999 | 3 | 0.010 |
Why?
|
| Monophenol Monooxygenase | 1 | 1999 | 10 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1999 | 50 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1999 | 44 | 0.010 |
Why?
|
| Body Weight | 1 | 1980 | 457 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1999 | 70 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1999 | 94 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 38 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1979 | 136 | 0.010 |
Why?
|
| Cell Separation | 1 | 1999 | 201 | 0.010 |
Why?
|
| Cell Communication | 1 | 1999 | 223 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1029 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 994 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 1976 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 557 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 737 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 4837 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1999 | 1460 | 0.010 |
Why?
|
| Indians, North American | 2 | 1980 | 49 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 2386 | 0.000 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1980 | 67 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1980 | 118 | 0.000 |
Why?
|
| Mexico | 1 | 1980 | 76 | 0.000 |
Why?
|
| Arizona | 1 | 1979 | 11 | 0.000 |
Why?
|
| Lipoproteins, LDL | 1 | 1979 | 87 | 0.000 |
Why?
|
| Lipoproteins, HDL | 1 | 1979 | 92 | 0.000 |
Why?
|
| Cholesterol | 1 | 1980 | 377 | 0.000 |
Why?
|